

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also PTO Form 3.76)

DEPOSIT ACCOUNT ORDER FORM

DATE

January 29, 2001

This form is to be used only for orders, the costs of which are to be charged against United States Patent and Trademark Office Deposit Accounts. IT MUST NOT BE USED FOR orders when payment is made by cash, checks, credit cards, or coupons. In addition, it should not be used for ordering printed copies of U.S. Patents. Use a separate form for each of the following types of service ordered: Recordings, Reproductions, Title Reports, Translations. Mail to: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

NAME AND ADDRESS FOR DEPOSITOR

Melissa A. Shaw
Bayer Corporation
800 Dwight Way
P. O. Box 1986
Berkeley, CA 94701

FOR OFFICE USE ONLY

ACCOUNT NUMBER

03-4000

YOUR ORDER NUMBER

MSB-7272

DESCRIPTION OF ARTICLES OR SERVICE TO BE FURNISHED

Please charge deposit account number 03-4000 the \$130.00
filing fees or any other filing fees for the following
notice to file missing parts enclosed with this authorization.

Title: Pituitary Adenylate Cyclase Activating Peptide (PACAP)
Receptor 3 (R3) Agonists and Their Pharmacological
Methods of Use

Inventors: Clark Pan et al.

If additional space is needed attach separate sheet.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Melissa A. Shaw
(signature)

For prompt, accurate shipment please complete the following mailing label - please print or type.

U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
Washington, DC 20231
OFFICIAL BUSINESS
Return after five days

MSB-7272

YOUR ORDER NUMBER

Melissa A. Shaw
Bayer Corporation
(name)
800 Dwight Way
(street address)
Berkeley, CA 94701
(city, state, zip code)

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231.




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/671,773	09/27/2000	Clark Pan	MSB-7272

Melissa A Shaw
Patent Department
Bayer Corporation
800 Dwight Way P
Berkeley, CA 9470



FORMALITIES LETTER



OC000000005632832

Docketed 1/5/01

Date Mailed: 12/21/2000

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing.
A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 130.

*A copy of this notice **MUST** be returned with the reply.*

Kim Duncan

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

02/09/2001 SDENB081 00000005 034000 09671773

01 FC:105 130.00 CH



Sector #

PATENT
MSB-7272

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail on the date indicated below and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Luzjuana LeGrande
Luzjuana LeGrande

January 30, 2001
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Pan et al.

Serial No.: 09/671,773

Filed: September 27, 2000

Title: Pituitary Adenylate Cyclase Activating
Peptide (PACAP) Receptor 3 (R3)
Agonists and Their Pharmacological
Methods of Use

RESPONSE TO NOTICE
TO FILE MISSING PARTS
AND CORRECTION OF
FILING RECEIPT

Attention: Box Missing Parts
Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

This is in response to the December 21, 2000 Notice to File Missing Parts of Nonprovisional Application. In addition, Applicant requests a correction of the title in the Filing Receipt, also mailed December 21, 2000, a copy is enclosed for your review. Please correct the word "phatmacological" to -- pharmacological--.

Transmitted herewith for filing are the following:

1. Notice to File Missing Parts of Nonprovisional Application (Part 2).
2. An executed Declaration for Patent Application.

3. A Deposit Account Order Form authorizing payment of the filing fee from Deposit Account 03-4000. Please also charge any additional fees due or credit any overpayment.

Dated: _____

1/30/01

Respectfully submitted,

Melissa A. Shaw

Melissa A. Shaw

Reg. No. 38,301

Attorney for Applicants

(510) 705-7901



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/671,773	09/27/2000	1641	1044	MSB-7272		31	5

Melissa A Shaw
Patent Department
Bayer Corporation
800 Dwight Way P O Box 1986
Berkeley, CA 94701



FILING RECEIPT



OC000000005632831

Date Mailed: 12/21/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Clark Pan, residence, NOT PROVIDED;
Manami Tsutsumi, residence, NOT PROVIDED;
Armen B. Shanafelt, residence, NOT PROVIDED;

Continuing Data as Claimed by Applicant

Foreign Applications

If Required, Foreign Filing License Granted 12/20/2000

Title

Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their
pharmacological methods of use
Pharmacological

Preliminary Class

435

Data entry by : DUNCAN, KIMBERELY

Team : OIPE

Date: 12/21/2000





**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231